Navigation Links
PSA velocity screening for prostate cancer may lead to unnecessary biopsies
Date:2/24/2011

Guidelines of several cancer organizations have recommended that men with a rapid rise in PSA have a biopsy for prostate cancer, even if there is no other indication and the PSA is within the "normal" range. But change in PSA known as PSA velocityis a poor predictor of prostate cancer, and may lead to many unnecessary biopsies, according to a study published online February 24 in the Journal of the National Cancer Institute.

Researchers have known for many years that PSA velocity is statistically correlated with prostate cancer risk. But little is known about how much PSA velocity adds to the value of other indicators or how useful it is to men and their physicians in making decisions about biopsies. And there has never been a study of PSA velocity in men who have had biopsies in the absence of a high PSA or a positive digital rectal exam.

Andrew Vickers, Ph.D., at Memorial Sloan-Kettering Cancer Center, and colleagues assessed how well PSA velocity predicted cancer (positive biopsy results) in 5,519 men who took part in the Prostate Cancer Prevention Trial. The men in this analysis were all in the group that received a placebo, so their prostate cancer risk was not influenced by the drug finasteride (Proscar), which was tested in that trial. All had a biopsy at the end of the study, regardless of their PSA levels, PSA velocity, or other indicators.

As expected, the authors found a statistical association between PSA velocity and biopsy outcome. But when they adjusted for other risk indicators, such as age, race, PSA levels, and digital rectal exam, there was virtually no association between PSA velocity and biopsy outcome.

"There was little evidence that PSA velocity adds an important level of predictive accuracy to either standard predictors or to PSA alone," they write.

The authors also evaluated guidelines stating that men with a rapid rise in PSA should have a biopsy even if their PSA is low and there are no abnormal findings on a clinical exam. The vast majority of the men who fell into this category (about 80%) did not have cancer, suggesting that use of PSA velocity would lead to many unnecessary biopsies. PSA alone was a better predictor of biopsy outcome in these men than PSA velocity.

"In other words," they write, "if a clinician feels that the current PSA thresholds are insufficiently sensitive, he or she would be better off identifying patients to biopsy by using low PSA thresholds than by adding PSA velocity as a criterion for biopsy."

The authors conclude that PSA velocity should not be included in prostate cancer screening guidelines.

In an accompanying editorial, Siu-Long Yao, M.D., and Grace Lu-Yao, Ph.D., of the Cancer Institute of New Jersey agree that the findings suggest that PSA velocity does not help doctors and patients decide what to do about screening results.

"PSA velocity measurements take time to acquire, and recognizing that such data add relatively little information may help prevent inappropriate postponement of follow-up in affected patients," they write. "Avoiding the wait to acquire subsequent PSA values may also help reduce some of the anxiety associated with testing." They go on to say that the results of this study serve to "remind us that the use of PSA as a screening tool still leaves much to be desired."


'/>"/>

Contact: Caroline McNeil
Caroline.McNeil@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. ATV and motocross sports - high velocity toys merit caution
2. Abatement Technologies Announces High-Velocity RAPTOR™ Air Movers for Water Damage Restoration Contractors
3. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
4. Screening mammograms catch second breast cancers early
5. Higher volume reduces false positives in screening mammography
6. Worlds largest lung cancer screening conference to address benefits of CT scans
7. Breast cancer screening with MRI benefits women with radiation therapy history
8. Screening for cervical cancer low for immigrant women
9. Repeat MRI screening for breast cancer results in fewer false positives
10. Study finds MRSA screening saves hospitals money
11. More Screenings May Explain Higher Chlamydia Rates Among Minorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the ... month as a Guest Speaker and Contributor to a weeklong series of classes, meetings, ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... , ... May 23, 2017 , ... New patients with ... chronic bad breath, can now receive laser gum disease treatments from the doctors at ... and David Landau are raising awareness of the importance of receiving qualified treatment in ...
(Date:5/22/2017)... ... 2017 , ... The American Academy of Thermology ... and clinical application of medical infrared imaging, has announced two new educational offerings ... services. , The first new educational offering is an online self-directed Physician Member ...
(Date:5/22/2017)... ... ... An inventor from Columbia, S.C., wants to offer people with manual disabilities ... a firework accident, so she couldn’t grip a pen properly," he said. "This inspired ... and created a prototype for the HELPEN HAND, a special pen that enables a ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
Breaking Medicine Technology: